Switch to: తెలుగు
Home Tags Sputnik v

First consignment of Sputnik V arrives in Hyderabad

Telugu360
-
0
First consignment of Sputnik V arrives in Hyderabad

The first consignment of 150,000 doses of the Sputnik V vaccine landed in Hyderabad from Russia, Dr Reddy’s Laboratories announced on Saturday.

A special cargo flight carrying the first consignment landed at Rajiv Gandhi International Airport.

Hyderabad Customs facilitated expeditious clearance of the vaccines imported from Russia.

The rollout of the consignment will be subject to the necessary clearances, which will be processed over the next few days, Dr Reddy’s said in a statement.

“This initial quantity will be used across different channels as a pilot to line up our supply chain for the larger vaccination program rollout,” it added.

Subsequent consignments will arrive in the next few weeks.

“First batch of Sputnik V has arrived in Hyderabad. That’s the same day the country starts mass Covid vaccination drive covering entire adult population. Let’s jointly defeat this pandemic. Together we are stronger,” tweeted Sputnik V.

Last month, the Indian regulators granted regulatory approval or restricted use authorisation to Sputnik V.

With an efficacy of 91.6 per cent, Sputnik V was the first vaccine against Covid-19 in the world.

Clinical trial data published in The Lancet indicated that the vaccine appears safe and effective.

Sputnik V will be the third vaccine to be cleared for use in India at a time when the country is in the grip of an intense second wave and demand for vaccines has shot up.

Dr Reddy’s top executives recently hinted that Sputnik V Covid vaccine will be sold at $10 (around Rs 750) a dose in India.

The company has entered into an agreement with Russian Direct Investment Fund (RDIF) for import of 125 million people equivalent doses.

Dr Reddy’s plan to ramp up manufacture of the vaccine in India after the initial imports.

Telugu360 is always open for the best and bright journalists. If you are interested in full-time or freelance, email us at Krishna@telugu360.com.

DCGI accords Dr. Reddy’s permission to import Sputnik V (Ld)

Telugu360
-
1
DCGI accords Dr. Reddy’s permission to import Sputnik V (Ld)

Dr. Reddy’s Laboratories (DRL), the city based pharmaceutical major on Tuesday said it received permission from the Drugs Controller General of India (DCGI) to import Sputnik V vaccine into India for restricted use in emergency situations.

“We are very pleased to obtain the emergency use authorization for Sputnik V in India. With the rising cases in India, vaccination is the most effective tool in our battle against Covid,” said DRL’s co – chairman and managing director G.V. Prasad.

According to the Hyderabad-based company, emergency use will be as per the provisions of the new drug and clinical trials rules, 2019 under the Drugs and Cosmetics Act.

The pharmaceutical major partnered with Russian Direct Investment Fund (RDIF) in September 2020 to conduct clinical trials of Sputnik V and distribute the vaccine in India.

“In addition to the trials conducted in Russia by RDIF. Phase II/III clinical trials of the vaccine were carried out by Dr. Reddy’s in India,” said a company official.

As per DRL’s statement, Sputnik V is approved to tackle coronavirus in 60 countries across the world, including ranking second among coronavirus vaccines globally in terms of the number of approvals issued by the government regulators.

“Sputnik V uses two different vectors for the two shots in a course of vaccination. The efficacy of Sputnik V was determined to be 91.6 per cent as per a published article in the Lancet, one of the world’s oldest and most respected medical journals,” said the official.

Considering the shortage of vaccines being experienced by many Indian states, DRL received DCGI’s permission within a day’s time after the subject expert committee (SEC) approved its application for the Russian vaccine candidate Sputnik V.

Telugu360 is always open for the best and bright journalists. If you are interested in full-time or freelance, email us at Krishna@telugu360.com.

Dr Reddy’s plans to launch Sputnik V in India in March

Telugu360
-
1

Dr Reddy’s Laboratories Ltd hopes to launch Russian Covid vaccine Sputnik V in India in March after obtaining Emergency Use Authorisation (EUA).

The pharma major expects the Phase 3 trials to be completed next month.

“About 70 per cent of the trials have already been completed. We hope to roll out the product in March,” said Deepak Sapra, Chief Executive Office, API & Pharmaceutical Services, Dr Reddy’s.

He said the Phase 3 trials will be completed in February after which data will be compiled and submitted to the Drug Controller General of India for EUA.

Addressing a virtual press conference to announce third quarter results of the company, he said the company was also gearing up for the production of Sputnik. Initially it will be a combination of import and local manufacturing.

He also revealed that the company is in talks with a couple of local manufacturers. It has already signed agreements for 125 million patient doses of Sputnik V in India.

The pricing of vaccine has not been decided yet. The company plans to cater to both government and private demand.

It was on January 15 that Dr. Reddy’s announced that it has received approval from the Drugs Control General of India (DCGI) to conduct Phase 3 clinical trials.

The trials are to be conducted on 1,500 subjects as part of the randomised, double-blind, parallel-group, placebo-controlled study in India.

In September 2020, Dr Reddy’s partnered with Russian Direct Investment Fund (RDIF) to conduct the clinical trials of the Sputnik V vaccine and for its distribution rights in India.

Sputnik V developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against Covid-19 based on the established human adenoviral vector platform.

The vaccine’s efficacy is confirmed at 91.4 per cent, based on data analysis of the final control point of clinical trials in Russia.

Currently Sputnik V is being administered as part of emergency use in 12 countries.

Meanwhile, Dr Reddy’s posted consolidated net profit of Rs 20 crore during third quarter against a loss of Rs 569.7 crore in the year-ago period.

Revenues for the quarter ending December were Rs 4,930 crore which was up 12 percent year on year and one percent over the second quarter.

“We continued with our growth momentum while maintaining EBITDA margins. The profits were impacted due to trigger based impairment charge taken on a few acquired products including gNuvaring. We are progressing well on the Phase 3 clinical trials for Sputnik V vaccine in India. We continue to focus on enhancing our product offerings to our patients to serve them better,” said Dr Reddy’s Co-chairman & MD, G.V. Prasad.

Telugu360 is always open for the best and bright journalists. If you are interested in full-time or freelance, email us at Krishna@telugu360.com.

TRENDING

Latest

css.php
[X] Close
[X] Close